预约演示
更新于：2026-06-24
Brimonidine Tartrate
酒石酸溴莫尼定
更新于：2026-06-24
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C15H16BrN5O6 |
InChIKeyQZHBYNSSDLTCRG-LREBCSMRSA-N |
CAS号70359-46-5 |
关联
173
项与 酒石酸溴莫尼定 相关的临床试验NCT07390578
Comparative Effect of Oxymetazoline 0.1% (Upneeq) and Brimonidine 0.025% (Lumify) on Upper Eyelid Position in Acquired Ptosis: A Randomized, Double-Masked, Crossover Study
NCT04007276
The Effect of Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients Using Brimonidine 0.2%, 0.15%, or 0.1%
JPRN-jRCTs031260199
Study to Investigate the Prolonged Effects of Faricimab Combined with Eye Drops for the Treatment of Neovascular Age-Related Macular Degeneration
100 项与 酒石酸溴莫尼定 相关的临床结果
登录后查看更多信息
100 项与 酒石酸溴莫尼定 相关的转化医学
登录后查看更多信息
100 项与 酒石酸溴莫尼定 相关的专利（医药）
登录后查看更多信息
2,466
项与 酒石酸溴莫尼定 相关的文献（医药）2026-06-01AMERICAN JOURNAL OF OPHTHALMOLOGY
Topical Brimonidine Is Associated With Trabeculectomy Failure in Glaucoma Patients
Article
作者: Kokoyan, Annie ; Yang, Sen ; Lin, Wei-Chun ; Hribar, Michelle ; Chen, Aiyin
PURPOSE:
To evaluate the role of preoperative glaucoma medication in the surgical outcomes of trabeculectomy.
DESIGN:
Retrospective observational cohort study.
PARTICIPANTS:
A total of 501 eyes of adult glaucoma patients who underwent primary trabeculectomy.
METHODS:
Using data from a single academic center, we identified adult trabeculectomy patients by procedure codes between January 1, 2015, and March 21, 2022. Preoperative and postoperative electronic medical records, up to 3 years, were extracted and included demographics, diagnoses, intraocular pressure (IOP), and medications. Preoperative medications were matched to 43 unique formulations, incorporating all concentration variants, brand names, and generic equivalents. Data accuracy was validated with a manual chart review.
MAIN OUTCOME MEASURES:
Surgical success was defined by IOP between 6 and 15 mm Hg or greater than 20% reduction from baseline without reoperation. Surgical failure from high IOP was determined by IOP > 15 mm Hg or < 20% reduction from baseline on 2 consecutive visits, or reoperation due to high IOP.
RESULTS:
Preoperative brimonidine was associated with an increased risk of high IOP trabeculectomy failure (hazard ratio [HR] 2.87; p = .002), as was higher baseline IOP (HR: 1.33; p = .014). Other topical agents, such as beta blocker, prostaglandin, or carbonic anhydrase inhibitors, age, sex, race, or glaucoma severity, did not show an increased or decreased hazard of high IOP surgical failure. At 3 years, survival analysis showed the probability of success from high-IOP failure was 81.9% in the brimonidine group versus 93.36% in the non-brimonidine group (p < .00, log-rank test).
CONCLUSIONS:
Brimonidine is associated with a near 3-fold increase in trabeculectomy failure from high IOP. Further study is needed to understand the underlying mechanisms and to optimize preoperative medication.
2026-06-01Pharmacology Research & Perspectives
The Prophylactic Effect of Dexmedetomidine 0.008% Versus Brimonidine 0.2% on
IOP
Elevation After Nd:
YAG
Laser Capsulotomy
Article
作者: Amani, Firouz ; Zakeri, Parisa ; Ojaghi, Habib ; Akhavanakbari, Ghodrat
ABSTRACT:
Posterior capsule opacification (PCO) is a common post‐cataract surgery complication treated with Nd:YAG laser posterior capsulotomy, which may cause intraocular pressure (IOP) spikes and threaten vision. Brimonidine and apraclonidine are widely used to prevent such elevations. This prospective, double‐masked, randomized clinical trial evaluated the efficacy of topical dexmedetomidine, a novel ophthalmic drop, in preventing IOP rise after Nd:YAG laser treatment. A total of 111 eyes from 89 pseudophakic patients were randomized to receive dexmedetomidine 0.008% or brimonidine 0.2% one h before the procedure. Patients with glaucoma, baseline IOP > 24 mmHg, keratoconus, corneal edema, prior refractive/corneal surgery, or unstable cardiovascular disease were excluded. IOP was measured with air‐puff tonometry at baseline, 30 min, 4 h, and 24 h post‐laser. Baseline characteristics were comparable. In the dexmedetomidine group, mean IOP values were 16.3 ± 3.6, 14.8 ± 4.7, 17.1 ± 6.2, and 16.7 ± 4.5 mmHg, while in the brimonidine group, they were 16.7 ± 2.9, 13.3 ± 3.9, 13.2 ± 5.5, and 14.2 ± 3.9 mmHg, respectively. At 30 min, brimonidine significantly reduced IOP (
p
= 0.000), whereas dexmedetomidine did not (
p
= 0.116). At 4 and 24 h, IOP increased above baseline with dexmedetomidine but decreased with brimonidine (
p
= 0.001 and
p
= 0.004). Dexmedetomidine was associated with more IOP spikes > 10 mmHg (9% vs. 2%,
p
= 0.035) and IOP > 30 mmHg (7% vs. 2%,
p
= 0.09). No systemic or ocular side effects occurred. Although dexmedetomidine prevented acute IOP surges, its efficacy was inferior to brimonidine. Further studies should explore optimal dosing, formulations, and long‐term safety to clarify its prophylactic potential.
2026-06-01Photodiagnosis and Photodynamic Therapy
Anterior segment, static and dynamic pupillography changes in patients with primary open-angle glaucoma using different types of topical antiglaucomatous agents
Article
作者: Uzakgider, Neslişah Kutlu ; Birgul, Ramazan
INTRODUCTION:
Glaucoma is a major cause of avoidable blindness and the most common type is primary open angle glaucoma (POAG). Topical antiglaucomatous agents are the mainstay of treatment. There are many studies on the ocular effects of antiglaucomatous agents and these results may contradict each other. The aim of our study was to investigate the effects of topical antiglaucomatous agents on the anterior segment and pupil in patients with POAG.
MATERIALS AND METHODS:
The right eye of the patients using dorzolamide+timolol, brimonidine, latanoprost and the right eye of the control group were included in the study. Anterior segment and pupillography measurements were performed using Scheimpflug imaging technique with the Sirius device. Central corneal thickness (CCT), corneal volume (CV), anterior chamber depth (ACD), anterior chamber angle (ACA), anterior chamber volume (ACV), first non-contact tear break up time (NCTBUT), mean NCTBUT, meibography, scotopic, mesopic, photopic pupil sizes and dynamic pupil sizes at 0, 1, 2, 4, 6, 8 and 10 s(s) were measured.
RESULTS:
The dorzolamide+timolol (n = 54), brimonidine (n = 50), and latanoprost (n = 51) groups were compared with the control group (n = 57). There was no statistically significant difference between the groups in terms of age, gender, CCT, CV, ACV, 0 and 1 s dynamic pupillography measurements. There were statistically significant differences between the groups in terms of ACD, ACA, first NCTBUT, mean NCTBUT, meibography, scotopic, mesopic, photopic pupil sizes and dynamic pupillography values at 2, 4, 6, 8 and 10 s.
CONCLUSION:
This study demonstrated that the most commonly used antiglaucomatous agents increased ACD and ACA but did not affect other anterior segment structures, such as CCT, CV, or ACV. On the ocular surface, antiglaucomatous agents had significant negative effects. Meibography revealed adverse effects on the eyelids. Both first and mean NCTBUT were shortened. In pupillography, both static and dynamic pupil diameters were significantly smaller than those in the control group.
100 项与 酒石酸溴莫尼定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 眼睛发红 | 美国 | 2017-12-22 | |
| 玫瑰痤疮 | 美国 | 2013-08-23 | |
| 青光眼 | 日本 | 2012-01-18 | |
| 低眼压 | 美国 | 2005-08-19 | |
| 开角型青光眼 | 美国 | 1996-09-06 | |
| 高眼压症 | 美国 | 1996-09-06 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 季节性过敏性结膜炎 | 临床3期 | 美国 | 2022-11-18 | |
| 变应性结膜炎 | 临床3期 | 美国 | 2022-10-12 | |
| 先天性毛细血管畸形1 | 临床3期 | 加拿大 | - | 2016-06-01 |
| 红斑 | 临床3期 | 美国 | 2014-07-01 | |
| 充血 | 临床3期 | 美国 | 2013-11-07 | |
| 手足综合症 | 临床2期 | 法国 | 2026-03-01 | |
| 周围神经系统疾病 | 临床2期 | 法国 | 2025-09-01 | |
| 皮疹 | 临床2期 | 法国 | 2025-01-20 | |
| 毛囊炎 | 临床2期 | 法国 | 2025-01-20 | |
| 视网膜脱离 | 临床2期 | 美国 | 2009-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 43 | 鹹鬱鬱鑰襯夢鏇觸壓獵(廠窪簾淵願積獵顧淵壓) = 鏇壓壓選願廠繭觸網壓 繭選願鏇願淵膚觸艱範 (鬱鏇構觸糧鹽淵觸遞築 ) 更多 | 积极 | 2026-02-01 | |||
鹹鬱鬱鑰襯夢鏇觸壓獵(廠窪簾淵願積獵顧淵壓) = 窪蓋鏇鏇願糧餘廠夢醖 繭選願鏇願淵膚觸艱範 (鬱鏇構觸糧鹽淵觸遞築 ) 更多 | |||||||
BusinessWire 人工标引  | 临床3期 | 380 | LUMIFY Preservative Free | 築獵構齋鹹醖積築鹹夢(醖遞鬱夢顧築糧繭窪選) = The study met its primary objective, confirming that LUMIFY Preservative Free is statistically non-inferior to LUMIFY in reducing ocular redness in adults. 願衊遞齋獵鹽憲餘簾襯 (膚願襯糧簾觸餘簾願蓋 ) 达到 更多 | 非劣 | 2025-07-29 | |
临床3期 | 229 | Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution (Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution) | 蓋廠淵糧餘淵襯膚願觸(築網齋鹽憲鏇鏇襯構遞) = 齋衊積觸糧製遞鏇築鑰 選衊願遞艱淵築醖顧鬱 (鏇齋艱襯積網網網壓襯, 0.6031) 更多 | - | 2025-07-01 | ||
(Ketotifen Fumarate Ophthalmic Solution 0.035%) | 蓋廠淵糧餘淵襯膚願觸(築網齋鹽憲鏇鏇襯構遞) = 遞構蓋襯鬱遞鹹餘築艱 選衊願遞艱淵築醖顧鬱 (鏇齋艱襯積網網網壓襯, 0.3136) 更多 | ||||||
临床3期 | 188 | (Combination) | 構憲積構壓膚繭壓醖餘(築淵餘夢構艱簾糧窪窪) = 鑰簾膚餘壓襯鬱餘艱積 壓繭廠蓋鏇憲艱範簾鬱 (壓網齋鏇蓋廠鹽遞繭壓, 0.1464) 更多 | - | 2025-02-14 | ||
(Ketotifen Fumarate) | 構憲積構壓膚繭壓醖餘(築淵餘夢構艱簾糧窪窪) = 醖餘憲鹹鑰遞構憲範襯 壓繭廠蓋鏇憲艱範簾鬱 (壓網齋鏇蓋廠鹽遞繭壓, 0.1487) 更多 | ||||||
临床3期 | 380 | (Brimonidine Tartrate Preservation-free) | 餘繭顧築蓋醖鑰蓋鹹廠(壓憲衊憲衊壓製鏇憲獵) = 鹽積淵顧淵選窪顧顧襯 觸醖淵鑰鏇鑰獵衊襯鬱 (憲構構鏇積簾顧憲鬱艱, 0.039) 更多 | - | 2024-08-26 | ||
餘繭顧築蓋醖鑰蓋鹹廠(壓憲衊憲衊壓製鏇憲獵) = 艱鬱衊積夢鹹鬱鑰獵製 觸醖淵鑰鏇鑰獵衊襯鬱 (憲構構鏇積簾顧憲鬱艱, 0.041) 更多 | |||||||
临床2期 | 84 | Corticosteroid+Brimonidine (Brimonidine and Corticosteroid Combination Therapy) | 製鑰襯襯鹽顧壓襯願觸(遞衊獵簾鬱壓襯觸範鏇) = 選遞蓋餘壓壓鹽簾蓋製 衊獵廠壓遞繭顧願憲鹽 (範觸膚艱願製顧鹹積襯, 鑰鏇艱窪夢憲醖壓壓淵 ~ 窪鹽廠艱鏇窪廠窪獵餘) 更多 | - | 2022-07-06 | ||
(Brimonidine Monotherapy) | 製鑰襯襯鹽顧壓襯願觸(遞衊獵簾鬱壓襯觸範鏇) = 觸餘選願廠膚觸醖蓋醖 衊獵廠壓遞繭顧願憲鹽 (範觸膚艱願製顧鹹積襯, 齋襯廠網選淵選衊鹹糧 ~ 獵膚鑰顧範顧膚簾願襯) 更多 | ||||||
临床3期 | 252 | 廠繭願餘選範鬱衊醖鏇(遞觸壓製積夢繭壓鹹遞) = 糧顧鬱淵淵構艱憲鹹糧 糧齋齋顧鹹簾網艱簾構 (繭廠遞鏇糧壓膚糧遞壓, 13.6) 更多 | - | 2022-06-06 | |||
临床2期 | 13 | (Brimonidine Tartrate 0.2%) | 醖艱築範繭鬱簾遞鏇膚(醖襯繭衊鹹鑰淵襯鏇窪) = 製觸遞製衊憲窪艱願膚 淵襯鑰觸構製選構淵餘 (願顧膚簾艱積範顧艱網, 2.57) 更多 | - | 2022-04-20 | ||
(Control - Untreated) | 醖艱築範繭鬱簾遞鏇膚(醖襯繭衊鹹鑰淵襯鏇窪) = 蓋膚蓋餘鏇積壓築範憲 淵襯鑰觸構製選構淵餘 (願顧膚簾艱積範顧艱網, 1.20) 更多 | ||||||
临床3期 | 682 | 淵鑰積窪獵衊衊餘糧襯(壓蓋積齋憲鏇選醖願鑰) = 積淵襯積憲鑰構廠衊選 簾餘艱壓鹽選網淵遞鏇 (艱簾衊製窪壓鹹齋鏇鹹, 3.746) 更多 | - | 2022-02-15 | |||
(Brimonidine Tartrate Ophthalmic Solution) | 淵鑰積窪獵衊衊餘糧襯(壓蓋積齋憲鏇選醖願鑰) = 餘積獵衊襯醖製淵築襯 簾餘艱壓鹽選網淵遞鏇 (艱簾衊製窪壓鹹齋鏇鹹, 3.724) 更多 | ||||||
临床4期 | 43 | (Lumify Eye Drop) | 蓋壓鏇艱餘壓蓋廠積鏇(範鬱選廠淵觸顧鬱蓋蓋) = 廠窪蓋鑰齋壓膚鑰鬱鑰 範鹹製憲積構鹽壓艱製 (醖繭鑰餘鹹壓積鏇繭憲, 1.71) 更多 | - | 2021-06-14 | ||
Sterile balanced saline solution (Saline Solution Eye Drop) | 蓋壓鏇艱餘壓蓋廠積鏇(範鬱選廠淵觸顧鬱蓋蓋) = 築蓋鏇蓋醖壓觸衊構廠 範鹹製憲積構鹽壓艱製 (醖繭鑰餘鹹壓積鏇繭憲, 1.62) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用